Atherosclerosis Deafness Diabetes Epilepsy Nephropathy (ADDEN) Syndrome

Atherosclerosis-deafness-diabetes-epilepsy-nephropathy syndrome is a very rare inherited disorder. It causes early, widespread hardening and narrowing of arteries (premature atherosclerosis). It also causes sensorineural hearing loss (deafness), diabetes mellitus, seizures (often photomyoclonic epilepsy), progressive brain and nerve problems, and kidney disease (nephropathy). In the small number of people described, artery disease can involve the aorta, kidney arteries, coronary arteries, and brain arteries. The neurologic problems may include cerebellar signs such as unsteady walking and coordination problems. Kidney disease can progress over time. This condition has been reported in only one family in the medical literature, so doctors consider it extremely rare. Because it is so rare, doctors are still learning about the exact gene cause and the inheritance pattern. A mitochondrial energy-production defect in kidney cells and fibroblasts has been reported (partial deficiency of complexes III and IV), which may help explain the multi-system features. NCBI+2Orpha+2

Atherosclerosis–deafness–diabetes–epilepsy–nephropathy syndrome is a very rare, inherited disorder that affects many body systems at the same time. People develop severe, early hardening and narrowing of arteries (atherosclerosis) in large and medium blood vessels, sensorineural hearing loss (deafness), diabetes mellitus, epileptic seizures (often with light-triggered muscle jerks called photomyoclonus), slowly worsening brain and balance problems, and progressive kidney disease (nephropathy). It has been described in two brothers in one family; no new families have been reported since 1994. Possible inheritance patterns include autosomal recessive or X-linked recessive. A partial deficiency of mitochondrial respiratory chain complexes (III and IV) was noted in kidney cells and fibroblasts, which might explain why energy-hungry tissues (brain, inner ear, kidneys, arteries) are affected. The condition is serious and often shortens life, mainly because of aggressive vascular disease and multi-organ failure. Wikipedia+1

---

Other names

This condition is also called:

• Feigenbaum–Bergeron–Richardson syndrome.

• Premature atherosclerosis with photomyoclonic epilepsy, deafness, diabetes mellitus, nephropathy, and neurodegenerative disorder.

• Atherosclerosis–hearing loss–diabetes–epilepsy–nephropathy syndrome. Wikipedia+2Global Genes+2

---

Types

Because only a single family has been reported, doctors do not divide this syndrome into formal subtypes. But for practical care, clinicians often think in system-based “types” to guide testing and treatment:

1. Vascular-dominant presentation. Early, severe narrowing of major arteries (aorta, coronary, renal, cerebral) drives symptoms such as hypertension, chest pain, stroke-like events, or kidney ischemia. NCBI

2. Neurologic-dominant presentation. Seizures (often photomyoclonic), cerebellar signs, and gradual neurological decline are most visible, with vascular and kidney features recognized later. NCBI

3. Renal-dominant presentation. Protein in urine and kidney function decline come first, with vascular, hearing, and diabetes features appearing over time. Mitochondrial respiratory chain defects in kidney tissue have been reported. NCBI

4. Multisystem balanced presentation. Hearing loss, diabetes, seizures, atherosclerosis, and nephropathy emerge together in adolescence or early adulthood. Wikipedia

Note: Because ADDEN is so rare, doctors also carefully check for more common mitochondrial syndromes (like MIDD or MELAS spectrum due to the m.3243A>G variant) that can mimic parts of this picture (diabetes, deafness, seizures, nephropathy). This helps avoid a missed diagnosis. PMC+1

---

Possible causes or contributors

These are not “everyday” causes like in common diseases. They are mechanisms or associated findings that may explain why this rare syndrome affects many organs.

1. Genetic change (pathogenic variant). The condition is genetic; the exact gene is not yet fully defined because so few people have been studied. Genetic & Rare Diseases Center

2. Abnormal energy production in cells. Partial defects of mitochondrial complexes III and IV have been reported in kidney and fibroblast cells, reducing ATP and harming tissues with high energy needs. NCBI

3. Early, diffuse artery injury. Widespread atherosclerosis of large and medium arteries leads to organ damage from reduced blood flow. NCBI

4. Renal artery disease. Narrowing of kidney arteries worsens blood pressure and kidney function. NCBI

5. Coronary artery disease. Premature plaque in heart arteries may cause chest pain or heart attacks. NCBI

6. Cerebral artery disease. Narrowing in brain vessels can trigger seizures or stroke-like symptoms. NCBI

7. Direct kidney cell dysfunction. Mitochondrial defects can harm filtering units (glomeruli) and tubules, causing protein leak and scarring. NCBI

8. Progressive neurodegeneration. Loss of cerebellar and other neurons leads to movement and coordination problems. NCBI

9. Photomyoclonic epilepsy. Light-triggered abnormal brain activity produces jerks or seizures. NCBI

10. Sensorineural hearing loss. Damage to inner-ear hair cells or auditory nerve reduces high-tone hearing. Wikipedia

11. Diabetes mellitus. Beta-cell dysfunction and insulin shortage lead to high blood sugar. (Also seen in mitochondrial diabetes such as MIDD.) MedlinePlus

12. Oxidative stress in vessels. Mitochondrial dysfunction increases oxidative injury to artery walls, promoting plaque. (Mechanistic link inferred from mitochondrial disease literature.) PMC

13. Inflammation in artery walls. Chronic low-grade inflammation helps plaque form and rupture. NCBI

14. Hypertension from renal disease. Kidney injury raises blood pressure, which accelerates atherosclerosis. NCBI

15. Lipid abnormalities. Some patients with early atherosclerosis have unfavorable cholesterol patterns. (Assess and treat even if data are limited in this syndrome.) NCBI

16. Endothelial dysfunction. Damaged vessel lining loses its protective role, encouraging plaque. NCBI

17. Autosomal or X-linked recessive inheritance (suspected). Suggested by the original family report (two affected brothers). Wikipedia

18. Maternal mitochondrial contributions (differential to consider). Some features overlap with m.3243A>G-related disorders that also cause deafness, diabetes, seizures, and kidney disease. PMC+1

19. Reduced kidney perfusion from large-vessel disease. Low oxygen and nutrient delivery harms nephrons. NCBI

20. Cumulative multi-organ stress. Combined effects of diabetes, high blood pressure, and mitochondrial dysfunction speed up organ decline. NCBI

---

Common symptoms and signs

1. Hearing loss, especially of higher tones; may be gradual. Wikipedia

2. High blood sugar with thirst, frequent urination, and fatigue (diabetes). NCBI

3. Seizures that can be triggered by flashing lights (photomyoclonic). NCBI

4. Unsteady walking or clumsiness from cerebellar problems. NCBI

5. Headache, weakness, or stroke-like episodes from brain artery disease. NCBI

6. Chest pain or shortness of breath with exertion (early coronary disease). NCBI

7. High blood pressure, often linked to kidney or renal artery disease. NCBI

8. Leg pain with walking (claudication) from artery narrowing. NCBI

9. Protein in urine or swelling from kidney dysfunction. NCBI

10. Dizziness or fainting, sometimes from rhythm problems or blood-flow issues. NCBI

11. Cognitive or memory decline as neurodegeneration progresses. NCBI

12. Vision symptoms, if retinal or brain blood vessels are affected. NCBI

13. Numbness or tingling, if nerves are involved. NCBI

14. Exercise intolerance, due to mitochondrial energy problems and vascular disease. NCBI

15. General fatigue and weight changes, often related to diabetes and chronic illness. NCBI

---

Diagnostic tests

A) Physical examination

1. Vital signs and blood pressure in both arms. Helps detect hypertension and large-vessel disease; unequal arm pressures may suggest aortic or subclavian narrowing. NCBI

2. Cardiovascular exam and vascular pulses. Diminished pulses or bruits (whooshing sounds) suggest arterial narrowing. NCBI

3. Neurologic exam. Checks gait, coordination, reflexes, and light-sensitivity to identify cerebellar signs and epilepsy risk. NCBI

4. Ear exam and bedside hearing checks. Screens for sensorineural hearing loss that fits the syndrome. Wikipedia

5. Edema check and urine dip in clinic. Finds swelling and proteinuria that point to nephropathy. NCBI

B) Manual/bedside tests

6. Ankle–brachial index (ABI). Simple cuff test comparing ankle and arm pressures to detect leg artery disease. NCBI

7. Orthostatic vitals. Looks for blood-pressure drops that may reflect autonomic involvement. NCBI

8. Vision field and fundus screening. Quick checks that can reveal retinal ischemia or neuropathy clues. NCBI

9. Bedside glucose monitoring. Confirms high or fluctuating blood sugar in suspected diabetes. NCBI

C) Laboratory & pathology tests

10. Fasting glucose and HbA1c. Confirms diabetes and its control level. NCBI

11. Lipid profile. Detects patterns that worsen atherosclerosis and guide treatment. NCBI

12. Serum creatinine and eGFR. Measures kidney function over time. NCBI

13. Urine albumin-to-creatinine ratio (ACR). Early marker of kidney damage from nephropathy. NCBI

14. Mitochondrial studies in tissue (selected cases). Kidney or fibroblast assays may show reduced activity of complexes III/IV, supporting the diagnosis. NCBI

15. Genetic testing. Rare-disease panels and (if clinically indicated) mitochondrial DNA analysis help rule in/out mimics like m.3243A>G-related MIDD/MELAS spectrum that share diabetes, deafness, seizures, and renal disease. PMC+1

16. Kidney biopsy (when safe/needed). Can document glomerular or tubular injury patterns and help management; in mitochondrial disorders, focal segmental glomerulosclerosis (FSGS) patterns are not uncommon. Oxford Academic+1

D) Electrodiagnostic tests

17. Electroencephalogram (EEG). Detects seizure activity; photic stimulation can reveal photomyoclonic responses. NCBI

18. Electrocardiogram (ECG) and, if needed, Holter. Screens for rhythm problems and ischemic changes in premature coronary disease. NCBI

E) Imaging tests

19. Vascular imaging tailored to symptoms—CT angiography or MR angiography of the aorta, kidney arteries, coronary arteries, and brain vessels—to map the severity and distribution of early atherosclerosis. NCBI

20. Brain MRI. Looks for ischemic changes or atrophy that match neurologic symptoms and seizure history. NCBI

Non-pharmacological treatments

Because no trials exist in this exact syndrome, the strategies below adapt established best practices from diabetes, CKD, epilepsy, hearing loss, and atherosclerosis care. They are realistic, clinic-ready, and can be combined under a multidisciplinary team.

1. Team-based care plan.
   Build a plan shared by cardiology, neurology/epilepsy, nephrology, endocrinology, audiology, dietetics, and rehabilitation. The goal is to coordinate visits, medications, labs, imaging, and safety monitoring, reducing duplication and gaps. Team-based care improves risk-factor control and outcomes in chronic cardiovascular and kidney diseases and is routine for complex epilepsy and hearing management. PMC+3AHA Journals+3KDIGO+3

2. Lifestyle heart protection.
   Daily movement, smoke-free living, blood-pressure control, sleep, stress reduction, and a plant-forward eating pattern are the backbone of slowing atherosclerosis. These measures are first-line in major prevention guidelines and help every vascular bed (heart, brain, kidney). AHA Journals+1

3. Medical nutrition therapy for diabetes and CKD.
   A registered dietitian can tailor carbohydrate quality/amount, sodium limits, protein targets for CKD stage, and potassium/phosphate adjustments if needed. Diet therapy is a cornerstone of ADA diabetes care and KDIGO CKD care and supports safer use of glucose-lowering drugs and blood-pressure medications. Wisconsin Academy of Family Physicians+2Diabetes Journals+2

4. Blood pressure self-monitoring.
   Home BP checks with a validated device help hit <130/80 mmHg targets for people with diabetes and CKD to lower cardiovascular and kidney risk. Education on proper cuff use and keeping a log supports clinical decisions. Diabetes Journals

5. Continuous glucose monitoring (CGM) or structured SMBG.
   CGM (or well-planned finger-stick profiles) improves time-in-range, flags hypoglycemia, and helps adjust therapy—especially when kidney disease alters drug clearance. The ADA endorses CGM across diabetes types when available. Wisconsin Academy of Family Physicians

6. Cardiorespiratory fitness program.
   Gradual aerobic and resistance training improves insulin sensitivity, blood pressure, lipid profile, and functional capacity; it also benefits mood and seizure threshold for some. Exercise is a core lifestyle therapy in cardiovascular and diabetes guidelines. (Programs should respect neurologic deficits and CKD limits.) AHA Journals

7. Evidence-based hearing rehabilitation.
   Timely fitting of hearing aids, assistive listening devices, and candidacy assessment for cochlear implantation if severe/profound loss. Modern adult cochlear-implant guidelines emphasize early referral and structured follow-up. Pair technology with communication training and (if useful) sign-language exposure to prevent language deprivation. Adult Hearing+1

8. Seizure self-management education.
   Identify triggers (sleep deprivation, stress, flashing lights), adhere to medication, and use safety strategies (shower instead of bath; avoid heights/operating machinery when uncontrolled). Education and shared decision-making are pillars of epilepsy care. International League Against Epilepsy+1

9. Photostimulation precautions.
   For photomyoclonic seizures, use screen filters, reduce screen brightness/contrast, 60-Hz lighting avoidance when possible, and consider blue-light–reducing settings. Counseling on visual triggers is standard in photosensitive epilepsy. International League Against Epilepsy

10. Renal-protective hydration and nephrotoxin avoidance.
    Keep steady fluid intake (unless restricted), avoid NSAID overuse, and inform clinicians about CKD before contrast imaging or new meds. These are core KDIGO safety practices. KDIGO+1

11. Lipid-aware nutrition plus statin adherence support.
    Dietary saturated-fat reduction and adherence coaching amplify statin benefits to slow atherosclerosis progression, per ACC/AHA prevention guidance. AHA Journals+1

12. Smoking cessation program.
    Behavioral counseling and pharmacotherapy (NRT, varenicline, bupropion) reduce CVD, CKD, and stroke risk. Cutting tobacco is among the most powerful risk-reducers in preventive cardiology. AHA Journals

13. Falls and balance therapy.
    Neurologic deterioration and hearing loss impair balance. Vestibular and balance-focused physical therapy lowers fall risk and maintains independence; it is a standard rehab approach in neurodegenerative conditions. Wikipedia

14. Sleep and apnea screening.
    Treating sleep apnea improves BP, insulin resistance, daytime alertness, and seizure control in some patients; screening is recommended in high-risk cardiometabolic disease. AHA Journals

15. Vaccination optimization.
    Influenza, COVID-19, pneumococcal, hepatitis B (in CKD), and zoster per age/CKD/diabetes status reduce infection-triggered decompensation of heart, kidney, and glycemia. (Follow national schedules.) Diabetes Journals

16. Medication reconciliation and deprescribing review.
    Quarterly checks reduce drug-induced kidney injury, interactions that lower seizure threshold, and polypharmacy risks in complex patients. This is central to CKD and neurology safety. KDIGO

17. Foot care and neuropathy prevention.
    Daily foot checks, proper footwear, and periodic podiatry visits prevent ulcers and amputations in diabetes; this remains a cornerstone of ADA care. Wisconsin Academy of Family Physicians

18. Cardiac and cerebrovascular symptom action plan.
    Teach fast response to chest pain, TIA/stroke signs (F.A.S.T.), and worsening claudication. Early action saves heart and brain tissue in aggressive atherosclerosis. AHA Journals

19. Psychological support and caregiver training.
    Mood disorders are common with epilepsy and chronic disease; counseling improves adherence and quality of life. Caregiver training supports safety and communication. International League Against Epilepsy

20. Advance care planning.
    Given progressive, multi-organ involvement, early discussions about goals of care and emergency preferences are appropriate and patient-centered. Wikipedia

---

Drug treatments

Because controlled trials don’t exist for this exact syndrome, choices follow condition-specific guidelines (lipids/ASCVD, diabetes + CKD, epilepsy, BP control). All doses must be individualized, especially with CKD. Below are representative, commonly used options and why they’re used.

1. High-intensity statin (e.g., atorvastatin 40–80 mg nightly or rosuvastatin 20–40 mg). Class: HMG-CoA reductase inhibitor. Time: daily long-term. Purpose: aggressively lower LDL-C to slow plaque growth in premature, diffuse atherosclerosis. Mechanism: upregulates LDL receptors, reduces hepatic cholesterol synthesis; pleiotropic anti-inflammatory effects. Side effects: myalgia, rare myopathy, transaminase rise; dose adjust with CKD for rosuvastatin. First-line in high ASCVD risk and familial premature disease. AHA Journals+1

2. Ezetimibe (10 mg daily) as add-on. Class: intestinal cholesterol absorption inhibitor. Purpose: further LDL-C reduction when statin alone is insufficient or not tolerated. Mechanism: inhibits NPC1L1 in small intestine. Side effects: GI upset, rare transaminase elevations (with statin). AHA Journals

3. PCSK9 inhibitor (evolocumab or alirocumab; per label dosing). Class: monoclonal antibodies. Purpose: major LDL-C lowering in very-high-risk atherosclerosis. Mechanism: blocks PCSK9, raises LDL-receptor recycling. Side effects: injection-site reactions, nasopharyngitis. AHA Journals

4. Aspirin (secondary prevention dose 75–100 mg daily) when indicated. Class: antiplatelet. Purpose: reduce recurrent cardiovascular/ischemic events if established ASCVD is present; not for routine primary prevention in low risk. Mechanism: irreversible COX-1 inhibition. Side effects: bleeding, dyspepsia. AHA Journals

5. ACE inhibitor (e.g., lisinopril 5–40 mg daily). Class: RAAS blocker. Purpose: BP control; albuminuria reduction to slow CKD; cardiovascular protection in diabetes. Mechanism: blocks angiotensin-converting enzyme; efferent arteriolar dilation. Side effects: cough, hyperkalemia, creatinine rise, angioedema. Diabetes Journals

6. ARB (e.g., losartan 50–100 mg daily) if ACEI intolerant. Similar purpose and renal benefits; monitor potassium and kidney function. Diabetes Journals

7. SGLT2 inhibitor (e.g., empagliflozin 10 mg daily; dapagliflozin 10 mg daily). Class: glucose cotransporter-2 inhibitor. Purpose: kidney and heart protection in diabetes with CKD; modest A1C reduction. Mechanism: blocks glucose/sodium reabsorption in proximal tubule; lowers intraglomerular pressure; CV benefits. Side effects: genital mycotic infections, euglycemic DKA (rare), volume depletion; check eGFR thresholds. Diabetes Journals+1

8. GLP-1 receptor agonist with CV benefit (e.g., semaglutide weekly, dulaglutide weekly). Class: incretin mimetic. Purpose: A1C lowering and ASCVD risk reduction, especially if SGLT2i not tolerated or additional control needed. Mechanism: glucose-dependent insulin secretion, appetite effects. Side effects: nausea, GI upset; watch gallbladder disease, pancreatitis history. KDIGO

9. Basal insulin (e.g., glargine or degludec) when A1C very high or symptomatic. Class: insulin analog. Purpose: reliable glucose control when insulin deficiency or severe hyperglycemia exists. Mechanism: replaces basal insulin. Side effects: hypoglycemia, weight gain; careful titration with CKD. ADA 2025 recommends GLP-1RA before insulin when feasible, but insulin remains essential in many cases. Wisconsin Academy of Family Physicians

10. Antiseizure medication (ASM): levetiracetam. Class: SV2A modulator. Purpose: first-line for focal/generalized seizures; well tolerated, minimal interactions. Mechanism: modulates synaptic vesicle protein. Side effects: mood changes, somnolence; dose adjust in CKD. Choice of ASM must be individualized to seizure type and comorbidities. International League Against Epilepsy+1

11. Valproate (for generalized epilepsies if appropriate). Class: broad-spectrum ASM. Purpose: control generalized seizures and myoclonus; may help photomyoclonic seizures. Mechanism: GABAergic effects, sodium/calcium channel modulation. Side effects: weight gain, tremor, teratogenicity; liver toxicity risk—use with caution and plan pregnancy counseling. International League Against Epilepsy

12. Lamotrigine (broad-spectrum ASM). Mechanism: sodium-channel modulation; favorable cognitive profile. Side effects: rash (rare SJS/TEN), titration required. Useful in generalized and focal epilepsies depending on phenotype. International League Against Epilepsy

13. Clonazepam (adjunct for myoclonus/photosensitivity). Class: benzodiazepine. Purpose: reduce myoclonic jerks; bridge during dose changes. Side effects: sedation, tolerance. International League Against Epilepsy

14. Thiazide or calcium-channel blocker for BP targets. Class: antihypertensive. Purpose: reach <130/80 to reduce CV/renal events. Mechanisms: natriuresis (thiazide), vasodilation (CCB). Side effects: electrolyte shifts (thiazide), edema (CCB). Diabetes Journals

15. Finerenone (if diabetic CKD with albuminuria despite ACEI/ARB). Class: nonsteroidal mineralocorticoid receptor antagonist. Purpose: additional kidney/CV protection. Side effects: hyperkalemia—monitor labs. KDIGO

16. Omega-3 ethyl esters for severe hypertriglyceridemia. Class: lipid-lowering agent. Purpose: pancreatitis prevention; may support residual risk reduction when TGs very high. Side effects: dyspepsia; drug interactions minimal. AHA Journals

17. Antiplatelet intensification (clopidogrel) for selected secondary-prevention patients. Class: P2Y12 inhibitor. Purpose: reduce recurrent events post-stent/MI or in high-risk situations per cardiology guidance. Side effects: bleeding. AHA Journals

18. Erythropoiesis-stimulating agent (CKD anemia, when indicated). Class: ESA. Purpose: treat symptomatic anemia after iron repletion. Side effects: hypertension, thrombotic risk—use under nephrology care. KDIGO

19. Phosphate binders (advanced CKD with hyperphosphatemia). Class: GI phosphate binders. Purpose: mineral/bone disorder management. Side effects: GI upset; avoid calcium overload. KDIGO

20. Loop diuretic (edema, hypertension with CKD). Class: diuretic. Purpose: volume control; symptom relief. Side effects: electrolyte loss, dehydration; careful dosing with kidney function. KDIGO

---

Dietary molecular supplements

Use supplements only as complements to guideline-directed therapy, checking interactions and kidney function.

1. Prescription-grade omega-3 (EPA/DHA). Dose per label. Function: lowers very high triglycerides; anti-inflammatory effects may modestly affect vascular risk. Mechanism: reduces hepatic VLDL-TG synthesis. Monitor for bleeding with antiplatelets. AHA Journals

2. Plant sterols/stanols (2 g/day). Function: modest LDL-C reduction by blocking intestinal cholesterol absorption; food-based strategy that complements statins/ezetimibe. Mechanism: competes with cholesterol at NPC1L1. AHA Journals

3. Soluble fiber (oats/psyllium ≈10–15 g/day). Function: small LDL-C and post-meal glucose improvements; supports satiety and weight control. Mechanism: bile acid binding, slower carbohydrate absorption. AHA Journals

4. Vitamin D repletion if deficient. Dose per labs. Function: bone/mineral health in CKD. Mechanism: corrects secondary hyperparathyroidism; follow KDIGO targets. KDIGO

5. Oral iron (or IV iron) when ferritin/TSAT low. Function: treat iron-deficiency anemia in CKD before/with ESA therapy. Mechanism: replenishes iron stores for erythropoiesis. KDIGO

6. Magnesium (only if low and safe in CKD). Function: arrhythmia and cramp reduction, possible migraine help; avoid in advanced CKD unless directed. Mechanism: cofactor in cellular electrophysiology. KDIGO

7. Potassium restriction (dietary adjustment) if hyperkalemia prone. Function: prevents dangerous potassium rises when on RAAS blockers or advanced CKD. Mechanism: reduces intake load. (Dietitian-guided.) KDIGO

8. Sodium restriction (~<2 g/day). Function: improves BP and fluid balance; crucial in CKD and heart disease. Mechanism: lowers extracellular volume and vascular stiffness. KDIGO

9. Protein tuning (≈0.8 g/kg/day in CKD, individualized). Function: slows CKD progression while preserving nutrition; higher during dialysis or illness per dietitian. Mechanism: reduces glomerular hyperfiltration and nitrogenous waste. KDIGO

10. Caffeine moderation for seizure control (if sensitive). Function: avoids sleep disruption/triggering in some people with epilepsy. Mechanism: adenosine receptor antagonism may lower seizure threshold in sensitive individuals. International League Against Epilepsy

---

Immunity-booster / regenerative / stem-cell drugs

There are no disease-modifying immune or stem-cell therapies proven for this syndrome. The items below reflect supportive therapies used in CKD/diabetes anemia and nutrition; anything “stem-cell” should be considered investigational only.

1. Erythropoiesis-stimulating agents (ESAs). Dose per protocol. Function: support red-cell production in CKD anemia to improve energy and function; not an immune booster. Mechanism: EPO-receptor agonism in marrow. KDIGO

2. IV iron (when indicated). Dose per ferritin/TSAT. Function: restore iron stores to enable effective erythropoiesis with or without ESA; improves oxygen delivery. Mechanism: replenishes bioavailable iron. KDIGO

3. Vaccinations (influenza, pneumococcal, hepatitis B, COVID-19). Dose per schedule. Function: prevent infections that can destabilize heart, kidney, and glycemia; this is the safest, evidence-based “immune support.” Mechanism: antigen-specific adaptive immunity. Diabetes Journals

4. Vitamin D (deficiency correction). Dose per labs. Function: supports innate/adaptive immunity and bone health; routine in CKD if low. Mechanism: vitamin D receptor–mediated immunomodulation. KDIGO

5. Nutritional optimization (dietitian-led). Ongoing. Function: adequate protein-energy intake, micronutrients, and fiber to support overall resilience. Mechanism: corrects deficiencies that impair immune function. Wisconsin Academy of Family Physicians

6. Clinical trials—stem-cell or gene-targeted approaches. None specific to this syndrome are established; enrollment only within regulated trials. Function/mechanism: investigational. Wikipedia

---

Surgeries/procedures

1. Coronary/vascular revascularization (PCI/CABG/carotid procedures) when indicated. Used for critical stenoses causing angina, infarct, TIA, limb ischemia. Decision-making follows standard chronic coronary and cerebrovascular disease guidelines. AHA Journals

2. Cochlear implantation (severe/profound sensorineural loss). For patients who do not benefit from hearing aids, cochlear implants can restore access to sound; success requires candidacy evaluation and structured rehabilitation. American Academy of Audiology

3. Arteriovenous access creation (for dialysis) in advanced kidney failure. Prepared before dialysis initiation to enable safe, long-term hemodialysis when needed. KDIGO

4. Kidney transplantation (selected cases). Offers superior survival and quality of life compared with dialysis in eligible CKD stage 5 patients; requires careful cardiac/neurologic evaluation in this syndrome. KDIGO

5. Epilepsy surgery or neuromodulation (rare, selected). If seizures are focal and drug-resistant, standard epilepsy pathways (pre-surgical evaluation; VNS/DBS/RNS) may be considered. International League Against Epilepsy

---

Prevention

1. Don’t smoke or vape; avoid secondhand smoke. AHA Journals

2. Keep BP <130/80 mmHg with home monitoring and treatment. Diabetes Journals

3. Keep LDL-C as low as possible for very-high risk; take statins as prescribed. AHA Journals

4. Use SGLT2 inhibitors and/or GLP-1 RAs in diabetes with CKD/ASCVD when eligible. KDIGO

5. Keep A1C individualized (often ~7% or per clinician) with hypoglycemia avoidance. Wisconsin Academy of Family Physicians

6. Follow kidney-safe habits (limit NSAIDs, contrast safeguards, diet changes). KDIGO

7. Follow seizure safety and sleep hygiene; avoid photic triggers if sensitive. International League Against Epilepsy

8. Stay up-to-date on vaccinations. Diabetes Journals

9. Maintain physical activity most days and a plant-forward diet. AHA Journals

10. See audiology early for hearing changes; earlier rehab works better. Adult Hearing

---

When to see a doctor

Seek emergency care now for chest pain, shortness of breath, signs of stroke (face droop, arm weakness, speech trouble), new severe headache, a prolonged seizure (>5 minutes), repeated seizures without recovery, or sudden hearing loss. These can be life-threatening in people with aggressive atherosclerosis and epilepsy. AHA Journals

Arrange urgent/soon visits for rising blood pressure, swelling, rapid weight gain, severe fatigue/pallor (possible anemia), frequent hypoglycemia or very high readings, new or worsening hearing problems, medication side effects, or decline in balance or memory. Timely adjustments reduce long-term damage. Diabetes Journals

---

What to eat and what to avoid

• Emphasize: vegetables, fruits, legumes, whole grains, nuts, seeds, olive/canola oils; fish 1–2×/week; low-fat dairy if tolerated; portion-controlled lean proteins; adequate but CKD-appropriate protein. These choices help BP, lipids, and glycemia. AHA Journals

• If CKD: work with a dietitian on sodium (<2 g/day), potassium (limit if high), phosphate (limit additives/colas/processed meats), and individualized protein (~0.8 g/kg/day unless otherwise directed). KDIGO

• Limit/Avoid: processed meats, refined carbs/sugary drinks, trans fats, excess saturated fats, heavy sodium, and high-potassium foods if you run high potassium. Alcohol in moderation or none if advised. KDIGO+1

---

FAQs

1. Is this the same as Alström or MIDD?
   No. Those conditions also include diabetes and hearing loss, but they have different genetic causes and typical features (vision loss and obesity in Alström; maternal inheritance in MIDD). NCBI+2MedlinePlus+2

2. How is this syndrome diagnosed?
   It is a clinical diagnosis based on the rare cluster of signs. Genetic cause is not fully established; work-ups exclude look-alikes and assess each organ system. Wikipedia+1

3. Are there specific genetic tests?
   There is no single known gene for this syndrome today; clinicians may order panels/exome sequencing to rule out other syndromes. Wikipedia

4. Can it be cured?
   No cure exists. Care focuses on aggressive risk reduction for atherosclerosis, seizure control, kidney and diabetes protection, and hearing rehabilitation. AHA Journals+2Diabetes Journals+2

5. Are statins and PCSK9 inhibitors really necessary?
   In aggressive, premature atherosclerosis, intensive LDL-C lowering is standard care to slow events. AHA Journals+1

6. Which diabetes drugs protect kidneys/heart?
   SGLT2 inhibitors and GLP-1 RAs with CV benefit are recommended in diabetes with CKD/ASCVD when eligible. KDIGO

7. What blood pressure goal should we aim for?
   For people with diabetes, <130/80 mmHg reduces CVD mortality and slows CKD progression. Diabetes Journals

8. What if hearing aids don’t help?
   Ask about cochlear implant evaluation; adult candidacy and follow-up are set out in clinical guidelines. American Academy of Audiology

9. Are flashing lights dangerous?
   Yes, for some. Photomyoclonic seizures can be triggered by light flicker; trigger avoidance and appropriate ASMs help. International League Against Epilepsy

10. Is kidney transplant an option?
    Potentially, if overall health allows; evaluation is complex because of the vascular and neurologic risks. KDIGO

11. Do lifestyle changes still matter with such a severe disease?
    Very much—they amplify drug benefits and reduce event risk in heart, brain, and kidneys. AHA Journals

12. Are there research trials?
    None targeted to this syndrome are known; consider registries or genetics-informed studies when available. Wikipedia

13. How fast does it progress?
    Published patients had rapid, diffuse atherosclerosis with multi-organ involvement and poor prognosis, though data are extremely limited. Wikipedia+1

14. What specialists should be involved?
    Cardiology, neurology/epileptology, nephrology, endocrinology, audiology, rehabilitation, and dietetics—coordinated care is essential. AHA Journals

15. Can family members be screened?
    Because inheritance is uncertain, relatives may benefit from cardiovascular risk assessment, hearing and glucose checks, and genetic counseling to discuss testing options. Wikipedia

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 25, 2025.